More Videos
SPECIAL REPORT
MOST SHARED
- Timeless and Time-Tested Warren Buffett Watch Predictions
- Should Homeowners Be Able To Walk Away From Mortgage?
- Goldman Sachs Party Ban: No Gatherings of 12 or More
- Dubai World Set to Restructure About $26 Billion of Total Debt
- Blue Nile CEO: 'We're Having the Best Cyber Monday Ever'
- Treasury Threatens Banks, Not Borrowers
- Oil Demand Sees Year-Over-Year Rise, First Since 2007
- Bove: 26 Banks May Need To Raise More Capital
- Nov. 30: Unusual Volume Leaders
- Notre Dame Fires Charlie Weis After 5 Seasons
- Treasury Threatens Banks, Not Borrowers
- We're Approaching a Market Bubble: Portfolio Manager
- Hershey Shares: What Options Are Saying
- Nov. 30: Unusual Volume Leaders
- Why Careful Shoppers Are Great for the Box Office
- Blue Nile CEO: 'We're Having the Best Cyber Monday Ever'
- Best Online Retailers to Buy Now: Internet Analyst
- ESPN The Magazine’s Body Issue: A Financial Success
- Cyber Monday: The Last Vestige of Dotcom Hype
- White House to Crank Up Pressure on Mortgage Industry
- Treasury Threatens Banks, Not Borrowers
- Dubai World to Restructure About $26 Billion of Debt
- Cramer: Dubai Can’t Sink These 6 Dividend Stocks
- Bove: 26 Banks May Need To Raise More Capital
- Lesson From Dubai: Start Cutting Risk In Your Portfolio
- Iranian Seizure of British Yacht Pushes Oil Above $77
- Should Homeowners Be Able to Stop Paying Mortgage?
- Buffett's Predictions For Next Year—And Every Year
PHARMA'S MARKET VIDEO
RSS FEED
Pharma's Market
Text Size 
Investors seem to be shrugging off another setback for drug giant Pfizer. Late yesterday the company announced it's stopping a late-stage clinical trial for a skin cancer drug because it looks like it doesn't work better than chemo.
You can read more about melanoma at the American Society of Clinical Oncology's brand new and improved web site (it just launched today).
Pharma investors should know the risks of drug development. Most products that get tested don't ever make it to market. And as we've seen in oh-so-many instances in recent years, even when they do get approved there's no guarantee that the results that were seen in big clinical trials are gonna hold up in the real world.
It's a risky business. But Pfizer [PFE
Loading...
()
] has had a run of bad luck, if you can call it that, lately. It started in late 2006 when its hoped-for successor to Lipitor failed. Then, late last year it paid billions of dollars to get out of the new, unsuccessful inhalable diabetic insulin business. Then, early this year safety issues cropped out for its new stop-smoking drug Chantix. And now this.
Miller-Tabak healthcare analyst Les Funtleyder writes in a research note to clients this morning: "Unfortunately the bad news continues for PFE and we do not see many positive catalysts in the near-term given pipeline issues and political headwinds; valuation and dividend (about a 6 percent yield) do provide some support on the downside however."
Goldman Sachs pharma analyst James Kelly had forecast $300 million in sales for the skin cancer drug in 2012. That's not huge for a company the size of Pfizer. But given the looming loss of the Lipitor patent and its relatively sparse drug development pipeline, the company needs every bit of new revenue it can generate.
So, Kelly is cutting his earnings estimate for 2012 by two cents. Goldman Sachs has done and wants to do more investment banking for PFE and it makes a market in the shares.
In the meantime, Pfizer is fighting for Lipitor. Take a look below at the new ad I mentioned in yesterday's post that the company has started running in the wake of the Vytorin/Zetia data that came out over the weekend. I don't recall ever seeing the image of a real heart--especially so prominently--in a drug ad like this one.
It's a stark contrast to Pfizer's recent Lipitor campaign with Dr. Robert Jarvik, the inventor of the artificial heart, that the company ended after the ads came under fire from several corners. So, perhaps PFE is going for a more science-driven, medical-driven look in the wake of that brouhaha.
The Pfizer news is also hurting shares of Medarex [MEDX
Loading...
()
] which would have received a royalty from PFE if the skin cancer drug worked. Pfizer says it is still testing it, though, on several other cancers.
 |
The New York Post |
Questions? Comments?
Data is a real-time snapshot *Data is delayed at least 15 minutes